MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MaxCyte, Inc.NASDAQ: MXCT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.05M fell 18.0% year over year, behind the +4.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 18.6% from the prior quarter. Over 3 fiscal years it compounded at +24.0% a year.
Context
- Depreciation & amortization amounted to 15.6% of revenue in FY2025, up 4.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -18.0% toward the trailing-twelve-month pace of +4.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.14M USD
- Year-over-year change
- +19.2%
- 4-year CAGR
- +37.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.14M | +19.2% |
| FY2024 | 2024-12-31 | 4.32M | -5.5% |
| FY2023 | 2023-12-31 | 4.57M | +69.2% |
| FY2022 | 2022-12-31 | 2.7M | +89.5% |
| FY2021 | 2021-12-31 | 1.42M | — |
Depreciation & Amortization vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's LTM Mar 2026 depreciation & amortization of $4.68M is the 3rd largest of the 11 companies compared; the peer median is $2.67M.
- Its year-over-year change of +4.5% is the 5th highest of 10, against a peer median of -0.3%.
- Depreciation & amortization amounts to 14.5% of revenue for MXCT, versus a peer median of 13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $6.56M | -25.2% | -28.2% | 19.0% | |
| LTM Mar 2026 | $4.68M | +4.5% | +24.0% | 14.5% | |
| LTM Mar 2026 | $4.56M | +11.6% | +9.7% | 7.9% | |
| LTM Mar 2026 | $3.97M | — | -20.6% | 3.5% | |
| LTM Mar 2026 | $3.65M | +35.4% | +111.4% | 589.8% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.69M | +7.8% | +29.0% | 91.1% |
| LTM Mar 2026 | $1.61M | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $627K | -41.1% | -39.6% | 0.6% | |
| LTM Mar 2026 | $589K | -20.5% | +16.3% | 1.3% | |
| LTM Mar 2026 | $499.37K | -27.3% | -29.2% | 2.6% | |
| Peer median (excluding MXCT) | $2.67M | -0.3% | +5.1% | 13.4% | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Depreciation & Amortization | 1.42M | 2.7M | 4.57M | 4.32M | 5.14M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.96M | 0 | 13.98M | 0 | 9.21M |
| Change in Working Capital | (1.64M) | (3.21M) | 3.82M | (751K) | (6.12M) |
| Accounts Receivables | (1.71M) | (6.69M) | 7.14M | 1.23M | 1.15M |
| Inventory | (1.41M) | (3.49M) | (4.53M) | 1.36M | 575K |
| Accounts Payables | 2.09M | (149.7K) | 3.25M | (1.88M) | (3.72M) |
| Other Working Capital | (624.7K) | 7.12M | (2.04M) | (1.46M) | (4.13M) |
| Other Non-Cash Items | 664.6K | 9.3M | (6.13M) | 9.88M | 1.99M |
| Operating Cash Flow | (10.68M) | (14.78M) | (21.69M) | (27.61M) | (34.41M) |
| Capital Expenditures | (3.83M) | (18.48M) | (3.7M) | (1.65M) | (1.77M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (1.77M) |
| Purchases of Investments | (268.68M) | (290.94M) | (255.1M) | (150.86M) | (126.29M) |
| Sales of Investments | 77.5M | 284.6M | 313.77M | 159.44M | 155.76M |
| Other Investing Activities | 4.6K | 0 | 9K | 0 | 0 |
| Investing Cash Flow | (195.01M) | (24.82M) | 54.98M | 6.93M | 25.94M |
| Debt Repayment | (4.99M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 236.08M | 2.89M | 269K | 2.06M | 656K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.63M | 0 | 1.87M | 0 | 0 |
| Financing Cash Flow | 234.72M | 2.89M | 2.14M | 2.06M | 656K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.03M | (36.72M) | 35.44M | (18.62M) | (7.82M) |
| Free Cash Flow | (14.51M) | (33.26M) | (25.39M) | (29.26M) | (36.18M) |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.